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Abstract
Since cardiac hypertrophy may be considered a cause of death at autopsy, its assessment requires a uniform approach. Common
terminology and methodology to measure the heart weight, size, and thickness as well as a systematic use of cut off values for
normality by age, gender, and body weight and height are needed. For these reasons, recommendations have been written on
behalf of the Association for European Cardiovascular Pathology. The diagnostic work up implies the search for pressure and
volume overload conditions, compensatory hypertrophy, storage and infiltrative disorders, and cardiomyopathies. Although
some gross morphologic features can point to a specific diagnosis, systematic histologic analysis, followed by possible immu-
nostaining and transmission electron microscopy, is essential for a final diagnosis. If the autopsy is carried out in a general or
forensic pathology service without expertise in cardiovascular pathology, the entire heart (or pictures) together with mapped
histologic slides should be sent for a second opinion to a pathologist with such an expertise. Indication for postmortem genetic
testing should be integrated into the multidisciplinary management of sudden cardiac death.
Keywords Autopsy . Cardiovascular diseases . Diagnostic
criteria . Hypertrophy . Quality in pathology
Introduction
The clinical and forensic pathologists are frequently faced with
increased heart weight and heart size, with or without increased
wall thickness or chamber dilatation at autopsy. The main chal-
lenge is to determine whether these features are physiological or
pathological, and if they could represent the substrate for
arrhythmogenesis or heart failure [1]. For example, in case of
sudden death, when the only finding is increased cardiac mass,
the pathologist should search for features which could suggest a
possible genetic etiology and eventually advice the families for
clinical and genetic counseling [2]. In clinical autopsies, espe-
cially those with complex multiorgan disease, the contribution
of heart failure (either left or right sided, or both) to the death of
a patient is frequently a matter of discussion.
Why is there a need for a document on the pathologic diag-
nosis of cardiac hypertrophy? This is a very important issue as
cardiac hypertrophy could be considered as a cause of death.
Assessment of the cardiac dimensions at autopsy requires a uni-
form approach, including terminology, a common methodology
to measure the heart weight, size, and thickness as well as a
systematic use of cut off values for normality. Interpretation of
these findings needs a proper knowledge of the pathologic
Key points
• Terminology should be used appropriately because the various terms are
not interchangeable.
• Heart weight and wall thickness should be always measured according
to the protocol and compared against tables. If it is not possible to
establish the predicted values, 500 g for male hearts and 400 g for
female hearts may be considered a reasonable cut off in adults.
• When the diagnosis of cardiac hypertrophy is established, secondary
forms (pressure and volume overload, compensatory, mixed
pathophysiology, toxicity) should be always considered.
•Histology ismandatory in assessing cardiac hypertrophy, especially to confirm
or exclude storage and infiltrativemyocardial disorders. Extensivemyocardial
disarray is typically observed in hypertrophic cardiomyopathy. Cardiac
myocyte hypertrophy is not useful as it is found in all types of hypertrophy.
• Cardiac hypertrophy can be due to inherited diseases pointing to a need
for cardiological screening of family members and postmortem genetic
testing when indicated.
• Cardiac hypertrophy could be considered as the cause of death after a
careful clinic-pathological evaluation and exclusion of other causes of
death (either natural or unnatural).
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backgrounds of hypertrophy, including “new” diseases and ad-
herence to the current insights obtained from clinical imaging
(echocardiography, computed tomography—CT, cardiac mag-
netic resonance—CMR).
The diagnostic work-up in the setting of cardiac hypertrophy
implies delineation of disease entities with hypertrophic hearts
including pressure and volume overload conditions, compensatory
hypertrophy, storage and infiltrative disorders, and cardiomyopa-
thies. A number of gross morphologic features can indeed point to
a specific diagnosis, such as concentric hypertrophy, biventricular
hypertrophy, outflow tract obstruction, thickening of the interatrial
septum, nodular thickening with calcification of the aortic valve,
systemic and other organ involvement, and obesity.
However, in order to reach a final diagnosis, systematic
histologic analysis is mandatory, integrated with special
stains, immunostaining, and transmission electronmicroscopy
(TEM) when appropriate.
This approach allows us to address the genetic form of
hypertrophic cardiomyopathy (HCM) which is currently con-
sidered as “primary” cardiomyopathy, where the major dis-
tinctive feature is histological disarray of myocytes [3–5].
Finally, in some cases, the cause of hypertrophy remains un-
explained after in-depth gross and histologic examination, and
it should then be designated idiopathic left ventricular hyper-
trophy (LVH).
The goal of our paper is therefore to provide a uniform
terminology and methodology to assess cardiac hypertrophy
at gross and histologic examination of the heart, and also
reference values available covering the range of “normal”
cardiac measurements. This will allow to perform clinic-
pathological correlation and to detect genetically determined
forms.
Terminology
The pathologist should be aware that cardiomegaly, cardiac
hypertrophy, and cardiac dilatation are not interchangeable
terms. The same applies for LVH and HCM. Patterns of myo-
cardial hypertrophy, whether physiologic or pathologic, con-
centric or eccentric, symmetric or asymmetric, as well as re-
gional “compensatory” hypertrophy should be clearly de-
fined. Table 1 lists the terms currently used for gross and
histologic features related to cardiac hypertrophy with proper
definitions.
Physiologic hypertrophy is typically observed in people
undergoing regular strenuous dynamic exercise (“athlete’s
heart”) and during pregnancy. It is defined as a balanced type
of eccentric hypertrophy.
Pathologic hypertrophy occurs due to volume and/or pres-
sure overload, storage and infiltrative disease, systemic disor-
ders, and cardiomyopathies. This leads mostly to concentric
hypertrophy with wall and septal thickening and a loss of
chamber cross-sectional area (mass/volume ratio increased).
Over time, this state can deteriorate into a disproportionally
increase in heart weight and dilated and eccentric forms of
hypertrophy, leading to chamber enlargement with loss of free
wall and septal thickness (mass/volume ratio decreased). In
Table 1 Definition of terms
Terminology Description/look for, helpful
Macroscopic
Cardiomegaly A big heart upon visual judgement of the size, transverse and longitudinal diameters can help
Cardiac hypertrophy Increased heart weight compared to normal predicted values (see reference table and calculator)
Concentric hypertrophy Increased heart weight without cavity dilatation, internal chamber diameter can help
The wall thickness is usually increased
Eccentric hypertrophy Increased heart weight with cavity dilatation, internal chamber diameter can help
The wall thickness may be normal, increased, or decreased in eccentric hypertrophy.
Symmetric LV
hypertrophy
Almost equal thickness of the entire LV and septum
Asymmetric LV
hypertrophy
The thickness is not uniform but increased either in the free wall or in the septum. The most frequent variant is asymmetric
septal hypertrophy with septal-to-posterior wall thickness ratio≥1.3
Microscopic
Myocyte hypertrophy Increase in cardiac myocyte diameter > normal value. Nuclei are also increased in size irregular and hyperchromatic
Interstitial fibrosis Increased deposition of connective tissue in the interstitium without myocytes loss. Special connective tissue stains can be
helpful
Replacement fibrosis Increased deposition of connective tissue following extensive myocytes loss. Special connective tissue stains can be helpful
Myocyte disarray Loss of normal alignment of cardiac myocytes, often arranged at oblique and perpendicular angles to each other
Can be either single myocyte or myocyte bundle disarray
Small vessel disease Marked medial and or intimal thickening of intramural arterioles (100–500 micron) wall with luminal stenosis. Special
connective tissue stains can be helpful
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some diseases, particularly primary myocardial diseases (i.e.,
dilated cardiomyopathy-DCM) or valve incompetence (see
for instance aortic incompetence), the cardiomegaly is charac-
terized in primis by eccentric hypertrophy, with or without
increased wall thickness, and without a preceding concentric
remodeling phase.
Methodology for macroscopic and histologic
examination of the heart in relation
to hypertrophy
Heart weight The heart should be weighted emptied of post-
mortem clots from both atria and ventricles, with aorta and
pulmonary artery transected 1 cm above their origin, and with-
out any attached tissue such as pericardium, mediastinal fat, or
lung.
The heart weight is the first and important piece of in-
formation that indicates cardiac pathology [1, 2, 6]. The
majority of hearts are weighed in the fresh state at autopsy.
It should be noted that, although most values reported in the
literature were based on measurements of formalin-fixed
specimens, these values are applicable to fresh specimens
because formalin fixation generally produces a slight
change in heart weight, to return to the original fresh weight
by three weeks [7, 8].
Wall thickness The heart is cut with a complete transverse
(short-axis) section at the mid-ventricular level and then fur-
ther parallel transverse slices of ventricles are performed at 1-
cm intervals towards the apex [2]. These slices are assessed
carefully looking for changes in the cut surface of the myo-
cardium and the endocardium of the left ventricular (LV) and
right ventricular (RV) cavities. We strongly recommend not to
dissect the myocardium with slices parallel to the endo-
epicardial surfaces because the opportunity for transmural, full
thickness histological analysis gets lost. Then, the basal por-
tion of the heart could be opened along the RV and LV out-
flow tract (LVOT) to assess the basal septum, the septal en-
docardium, and the anterior mitral valve leaflet with special
attention to the geometric shape of the LVOT and presence of
endocardial friction lesions.
The individual ventricular wall thickness should be mea-
sured at the mid-cavity level, between the cardiac base and
apex, to the nearest 0.5 mm and must exclude trabeculae and
epicardial fat [1, 2, 9, 10]. The measurements should be taken
at the mid portion of the posterior wall of the LV and RV as
well as mid-septum. The major challenge is to obtain an ac-
curate measurement of the septum, given that pathologists
frequently overestimate its thickness by incorporating trabec-
ulae, such as the flattened septo-marginal trabeculation on the
right side.
In the presence of asymmetric hypertrophy, more measure-
ments will be taken to compare the septum and free wall
segments at different sites.
Photographic documentation with a ruled reference scale
should be made, before proceeding for histology.
When evaluating heart wall thicknesses at autopsy, post-
mortem phenomena such as rigor mortis or putrefaction have
to be considered. It is well known that postmortem thickness
could differ from echocardiographic values as measures are
more in keeping with systolic than diastolic in vivo values
[11]. Increased concentric thickness of the LV wall with small
cavity and heart weight within normal limits could be related
to rigor mortis [1]. With putrefaction, there will be
discolouration and thinning of both RV and LV walls with
artefactual chamber dilatation but in this case heart weight is
usually normal or even diminished depending on the degree of
putrefactive changes.
Heart size The transverse size (width) of the heart is best
calculated as the distance from the obtuse to the acute margin
at the posterior atrio-ventricular sulcus. The longitudinal size
(length) is obtained as the distance between the crux cordis
(i.e., the point at which the atrio-ventricular sulcus meets the
posterior interventricular sulcus) and the apex of the heart on
the posterior aspect [2, 12]. Measurements of ventricular
chamber sizes have been proposed at the midventricular level
at cross section but there is no clear consensus [13]. The as-
sessment of atrial size at autopsy is even more challenging.
Thus, besides the evaluation of chamber sizes, pathologic
changes in the lung and liver, serous effusions, and peripheral
edema can indicate acute or chronic heart failure at
postmortem.
In each case, and particularly when dealing with cardiac
hypertrophy, the aortic valve and aortic arch (isthmus) should
be carefully investigated to exclude causes of pressure
overload.
Diagrams to illustrate how to measure the wall thicknesses
and cardiac size are illustrated in Fig. 1.
Size of the heart in postmortem imaging A first idea of heart
size can be obtained radiologically by measuring the cardio-
thoracic ratio (CTR). The postmortem CTR is influenced by
body mass index (BMI) and the heart dilatation that could be
related to perimortem phenomena [14] and cannot be used
alone to discriminate between normal and increased heart
mass. A formula of adjusted CTR-based score could help to
predict “cardiomegaly” at postmortem computed tomography
(PMCT) [15]. Several studies showed that postmortem radio-
logical measurements of wall thicknesses including PMCT
and postmortem magnetic resonance (PMMR) differ from
corresponding autopsy measurements [16–20]. It was shown
that LV wall thickness was significantly higher on PMCT
compared to PMMR and that LV anterior wall thickness
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was significantly higher on PMMR than at autopsy [17].
PMCT was suggested as a helpful tool for the assessment of
LV mass, which is important in clinical practice [21]. Further
work is needed to correlate postmortem imaging with autopsy
values.
Histology and additional tools Standard histologic examina-
tion of the myocardium requires mapped labeled blocks (var-
iable in number depending on the size of the heart) from a
representative transverse slice of the ventricles to include the
LV wall (usually anterior, lateral, and posterior), the ventric-
ular septum (usually anterior, middle, and posterior), and the
RV free wall (usually anterior, lateral, and posterior), as well
as RV outflow tract [2]. LV myocardial sections should in-
clude the papillary muscles. Additionally, one block from any
area with significant macroscopic abnormalities should be
taken. Hematoxylin and eosin and a connective tissue stain
(elastic van Gieson, trichrome, or Sirius red) are routinely
performed. Other special stains and immunohistochemistry
should be performed as required particularly if there is a sus-
picion of storage or infiltrative disorders. The appropriate im-
munohistochemistry stains to diagnose specific forms of stor-
age and infiltrative disorders are reported elsewhere [22].
TEM can be of help in the latter conditions as well as in
mitochondrial disorders. Ideally, if one is suspecting an infil-
trative, storage, or mitochondrial disorder, samples of myo-
cardium should be placed in glutaraldehyde at the time of
autopsy as working later from paraffin-embedded tissue may
only have limited success. However, this is not feasible in
routine practice.
Definition of normal heart in relation
to hypertrophy
Gross examination Transverse and longitudinal dimensions of
the heart are useful parameters to judge cardiac size; however,
normal values according to body size are mostly missing.
According to Gray’s Anatomy, the heart length and width
are 12 cm and 8.5 cm [12]. More recently, length and width
have been investigated in different age groups in the Iranian
population, with mean values of 11.41 ± 2.15 cm and 8.21 ±
4.38 cm, respectively [23].
However, the heart weight is the most important param-
eter in the determination of cardiac hypertrophy. The ob-
tained heart weight value should be compared against ta-
bles of normal weights by age, gender, and body weight
and height [6, 9, 10]. The weighing of the body and
Fig. 1 a Diagrams illustrating the three cross sections of the hearts: the
first mid-ventricular one and at least two additional parallel sections
towards the apex. b On the left: left ventricular (posterior), septal
(middle), and right ventricular (posterior) thickness measurements, by
excluding trabeculae and papillary muscles. On the right: transverse
size and longitudinal size measurements on the posterior aspect of the
heart. ALMV, anterior leaflet mitral valve; ALPM, antero-lateral
papillary muscle; IVC, inferior vena cava; LV, left ventricle; LVFW,
left ventricular free wall; LSPV, left superior pulmonary vein; LIPV,
left inferior pulmonary vein; PLMV, posterior leaflet mitral valve;
PSPM, postero-septal papillary muscle; RIPV, right inferior pulmonary
vein; RSPV, right superior pulmonary vein; RV, right ventricle; RVFW,
right ventricular free wall; SVC, superior vena cava; VS, ventricular
septum
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measuring of the height are essential in all autopsies. Other
anthropometric data, such as abdominal circumference that
are related to cardiovascular risk factors, can be taken but
the clear relationship with the heart weight has not been
established yet. There are many studies proposing normal
values for heart weights, with a large variability of meth-
odology and obtained values (Supplemental Table 1) [9,
24–38]. It is stressed in the literature that reference tables
should be established for local population and periodically
updated [6, 25]. The most frequently cited reference
values for the heart weight are from Zeek et al. and
Kitzman et al. [9, 35], and are based on the data published
respectively in 1942 and 1988 concerning the North
American population.
More recently, it has been shown in the Swiss population
that the heart weight increases along with the increase of the
body weight, body height, BMI, and body surface area (BSA).
The mean heart weight is greater in men than in women at a
similar body weight. The reference tables for predicted heart
weights were presented as a user-friendly internet application
(http://calc.chuv.ch/Heartweight) enabling the comparison of
heart weights observed at autopsy with the reference values [6].
If it is not possible to establish the predicted values, 500 g
in adults male and 400 gr in adult female may be considered a
reasonable cut-off [39].
Ventricular wall thicknesses for adults from 20 to 99 years of
age were published by Kitzman et al. [9]. The mean thickness of
the RV freewall was 3.8mm (SD; 0.9mm) and the LV freewall
was 12.3 mm (SD 1.6 mm). The mean ventricular septal thick-
ness was 13.6 mm (SD 2.0 mm) (Fig. 2). The ventricular wall
thicknesses were similar for women and men and thickness of
the RV and LV free walls, indexed by BSA, remains relatively
constant through adult life. An appreciable increase in indexed
ventricular septal thickness was observed through to the 10th
decade of life. Summing up, we can consider abnormal values
those exceeding the reference range, i.e., a LV wall thickness
>14 mm, a RV wall thickness >5 mm, and a ventricular septal
thickness >15 mm [1, 40].
In children, predicted normal ventricular wall thicknesses
for females and males under the age of 20 years were
Fig. 2 Normal heart vs. cardiac
hypertrophy. a Cross section of a
normal heart in a perinatal death:
the right ventricular free wall
thickness is 3.5 mm, the left
ventricular is 5 mm, and the
septum 5.5 mm. b Cross section
of a normal adult heart: the right
ventricular free wall thickness is 2
mm, the left ventricular is 12 mm,
and the septum 13 mm. c Cross
section of hypertrophic heart in an
adult: the right ventricular free
wall thickness is 7 mm, the left
ventricular is 21 mm, and the
septum 22 mm. d Histology of a
showing hypercellularity which is
normal for a perinatal
myocardium (high number of
cardiac myocyte/myocardial area)
(bar = 100micron). eHistology of
b with diameter of cardiac
myocytes within normal values
(mean diameter 12 micron) (bar =
100 micron). fHistology of cwith
cardiac myocyte hypertrophy
(mean diameter 20 micron) (bar =
100 micron)
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published by Scholz et al. in 1988 [10]. In this age group, the
mean (and upper 95%) values are presented in the
Supplemental Table 2.
HistologyThemyocardium is composed of cross-striatedmus-
cle cells (cardiac myocytes) enveloped in a loosely arranged
extracellular matrix (interstitium). The cardiac myocytes ac-
count for about two-thirds of the myocardium by cell volume
but only for one-third by cell number. A healthy adult cardio-
myocyte is cylindrical in shape and measures approximately
100 μm in length (the myocyte length is impossible to measure
on routine sections) and up to 15 μm in diameter; the best way
to measure the diameter is on cross section when the nucleus is
located centrally in the muscle cell [41, 42] (Fig. 2). However,
these values should be further evaluated in future, by applying
digital microscopy systematically on cardiomyocyte sizes in
relation to heart weights and age at autopsy. The interstitium
contains microvessels and also some extravascular cells such as
fibroblasts, macrophages, lymphocytes, and mast cells.
Patterns of cardiac hypertrophy
Diagrams ofmacroscopic patterns of cardiac hypertrophy as
defined in Table 1 are exemplified in Fig. 3. Gross pictures of
hearts with various patterns of cardiac hypertrophy are illus-
trated in Figs. 4, 5, 6, 7, 8, 9, and 10.Macroscopic features that
should be considered in the differential diagnosis of the vari-
ous conditions leading to LVH are reported in Table 2.
RV hypertrophy is usually seen in the setting of left-sided
heart diseases, pulmonary diseases, and congenital heart
diseases. It may also occur in HCM, Anderson-Fabry, and
Noonan syndrome.
Microscopic patterns The term myocyte hypertrophy refers to
an increase in cardiac myocyte diameter >15 μm, measured in
cross section at the nuclear level. Other histologic character-
istics of cardiac myocyte hypertrophy are the presence of nu-
clei which are also increased in size, irregular, and
hyperchromatic due to increased DNA ploidy resulting from
DNA replication in the absence of cell division (Fig. 11).
Table 1 lists the histologic features with proper definitions
related to the wide spectrum of acquired and genetic forms of
cardiac hypertrophy, as mentioned before.
With the exception of storage, infiltrative, and cardiomy-
opathies, in all conditions of adaptive hypertrophy (pressure/




Primary cardiac hypertrophy (HCM and DCM)
HCM is the most common genetically determined primary
heart muscle disease, affecting 0.2–0.5% of the general pop-
ulation. The pattern of inheritance is autosomal dominant,
mostly due to mutations in genes encoding for sarcomeric
proteins (most often β-myosin heavy chain and myosin-
binding protein C). HCM is characterized by extreme pheno-
typic heterogeneity with either symmetric or asymmetric

















Atrial septum thickening - - - + + - - -
RV hypertrophy + - - + + - - -
Asymmetric LV
hypertrophy
+ + - + + - + -
Symmetric LV hypertrophy + + + + + + - +
LVOT bulging + + + - - - - -
LVOT endocardial plaque + - - - - - - -
Scarring + + + + + + + -
Papillary muscle
abnormalities
+ - - - - - - -
AV valve thickening - - - + + + - -
Endocardial wrinkling - - - + - - - -
Malformation syndromes, neuromuscular disorders, and mitochondrial diseases are excluded (clinical history, external examination, and other organs
involvement usually help). # Other organ/tissue involvement
For an overview of causes of cardiac hypertrophy, see Elliott P. et al. [5]
+ stands for can be seen
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pattern of LVH. In the latter, the interventricular septum is
markedly thickened relative to the LV free wall, although the
free wall can also exhibit asymmetric hypertrophy (Fig. 5).
Subaortic bulging leading to LVOT obstruction, with or with-
out septal endocardial plaques (“friction lesion”), can be ob-
served. A significant variability in the regional wall thickness
is reported [43, 44]. Less common variants of HCM include
those with regional wall thickenings involving the mid-septal
wall, the apex, the anterior-lateral, and posterior-basal free wall.
All LV segments from base to apex have to be examined since
LVH can be confined only to one or two segments. The disease
can occasionally progress to heart failure (end-stage HCM) due
Fig. 3 Diagrams illustrating
various patterns of cardiac
hypertrophy. a Symmetric,
concentric. b Symmetric,
eccentric. c Asymmetric septal. d
Asymmetric antero-lateral. e
Biventricular. f Right ventricular
Fig. 4 Cardiac hypertrophy. a
Concentric type (with increased
LV wall thickness). b Eccentric
type (with increased LV cavity)
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to extensive scarring with a markedly dilated ventricular cavity
[45]. A grossly visible whorled cut surface, reflecting the his-
tologic disarrangement of cardiac myocytes, is sometimes ap-
preciable when examining the heart either fresh or after fixa-
tion. Scarring can be more evident after fixation (supplemental
figure). Myocyte hypertrophy, architectural disorganization
(so-called disarray), and interstitial fibrosis are histopathologic
features of HCM (Fig. 12). However, myocyte disarray is not
pathognomonic of HCM, and can also be observed in other
heart diseases, including congenital heart diseases, as well as
in normal hearts, where it is physiological at the ventricular free
wall–septal junctions or in the trabeculae [46, 47]. The exis-
tence of HCM with normal heart weight and thickness (i.e.,
HCM without hypertrophy) but with widespread myocyte
disarray at histology is recognized [48]. Myocardial bridge
(i.e., a deep intramyocardial course of the left anterior descend-
ing coronary artery) is much more frequent in HCM than in the
normal heart [49]. Intramural small vessel disease, due to cel-
lular or fibrous intimal thickening and medial hypertrophy or
fibrosis, is another common histopathologic finding in HCM.
Ischemic myocardial injury, with either myocyte necrosis or
chronic fibrous scars, is often present [50]. Although in most
cases HCM can be discriminated from secondary hypertrophy,
e.g., due to hypertension, this is not always the case. Especially
in hypertrophic hearts with symmetric hypertrophy and without
significant myocyte disarray, the discrimination can be difficult
by histopathology alone. In all these cases where doubt remains
after the heart examination, it is very important to advice
Fig. 5 “Primary” cardiomyopathies. a Asymmetric septal hypertrophic cardiomyopathy with septal/LV free wall thickness ratio >1.3. b Asymmetric
antero-lateral hypertrophic cardiomyopathy. c Dilated cardiomyopathy with biventricular dilatation
Fig. 6 “Secondary” cardiomyopathies. a Concentric biventricular
hypertrophy in storage disease/glycogenosis. d Histology of a showing
diffuse cardiac myocytes vacuolization (hematoxylin eosin stain bar =
100 micron; insert TEM with intracellular glycogen deposits). b
Concentric biventricular hypertrophy in storage disease/Fabry disease. e
Histology of b showing extensive vacuolization of the cardiac myocytes
(hematoxylin eosin stain bar = 100 micron; insert TEM with concentric
lamellar bodies). e Concentric biventricular hypertrophy in infiltrative
disease/amyloidosis. f Histology of c with amorphous material
deposition in the interstitial space (hematoxylin eosin stain bar = 100
micron; insert shows the amorphous Congo red–positive substance at
polarized light)
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additional molecular autopsy in the context of screening of
first-degree family members via a cardiogenetic center to fur-
ther evaluate the diagnosis of familial HCM.
DCM encompasses etiologically heterogeneous myocardi-
al disorders that are defined by increased heart size, LV or bi-
ventricular dilation with decreased ejection fraction, in the
absence of hypertension, valve disease, and coronary artery
disease. DCM prevalence reaches 1/250–500 in clinical prac-
tice. A positive familial history can be detected in up to 30–
50% of cases, and a genetic determinant can be identified in
up to 40% of cases. Sarcomeric, mitochondrial, and neuro-
muscular disorders are frequent etiologies in the presence of
a familial history, where additional acquired conditions like
exposure to toxics, diabetes, arrhythmia, myocarditis, and
pregnancy can also account for DCM.
Macroscopically, increased heart weight and size with pre-
served or decreased LV wall thickness are typical of DCM
(Fig. 5). Endocardial fibrous thickening can be observed in
long standing cases due to thrombus organization. Mural
thrombi can be found. Endocardial fibroelastosis can be pres-
ent both in adults and children.
Myocyte hypertrophy can be seen at histology, together
with degenerative changes/cytoplasmic rarefaction/
vacuolization and irregular/abnormal nuclei with perinuclear
halo [51–53]. Interstitial fibrosis with or without replacement
type fibrosis is described. There is no direct match between
the pathologic findings and the etiopathogenesis, so that for
instance alcoholic cardiomyopathy and DCM of other causes
are not distinguishable.
Cardiac hypertrophy due to storage or infiltrative
diseases (Fig. 6)
There are specific heart muscle diseases that may account for
either concentric or eccentric cardiac hypertrophy in the set-
ting of systemic disorders. They include disorders that may be
localized to the myocardial interstitium (amyloidosis) or with-
in myocardial cells (Iron Heart Disease-Hemochromatosis;
storage disease such as Anderson Fabry’s disease with de-
posits of ceramide trihexoside, Pompe’s disease—type II gly-
cogen storage disease, Gaucher’s disease with glucosyl cer-
amide lipidosis). The detailed presentation of these entities is
out of the scope of this document. For an overview of causes
of cardiac hypertrophy, we suggest to check the pertinent lit-
erature [5]. Special histological stains and, in selected cases,
TEM are crucial for the final diagnosis.
Cardiac hypertrophy due to pressure overload
(concentric hypertrophy) (Fig. 7)
– Hypertensive heart disease. At autopsy, by far the most
common form of LVH relates to systemic hypertension.
This results from longstanding pressure overload due to
increased peripheral resistance. The hypertensive heart
Fig. 7 Cardiac hypertrophy due
to pressure overload. a
Hypertensive heart disease. b
Aortic valve stenosis due to
dystrophic calcification
Fig. 8 Compensatory
hypertrophy. a Chronic ischemic
heart disease with previous lateral
myocardial infarction. b
Subacute-chronic myocarditis
with mild left ventricular
hypertrophy
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frequently shows coexistence of atherosclerotic coronary
artery disease and enlarged left atrium. With time, signif-
icant hypertension with gradual stiffening of the LV wall
results in eccentric type of hypertrophy with concomitant
dilatation of the cavity and eventually a pattern difficult to
discriminate from DCM [54].
– Valve diseases. Similar to hypertension, any obstructive
disease of the LVOT and aorta causes LV pressure over-
load. These include aortic valve stenosis (congenital-
unicuspid, bicuspid, and tricuspid- or acquired-senile
dystrophic calcification or rheumatic), sub- and
supravalvular stenosis, and aortic isthmic coarctation.
Also similar to hypertension, LVOT obstructions may
end up in a volume overload type of LVH with chamber
dilatation.
Hypertrophy due to volume overload (eccentric
hypertrophy)
Physiologically it occurs in endurance athletes (running,
swimming) and during pregnancy, due to increased preload.
Pathologically, all diseases leading to aortic valve regurgi-
tation and/or mitral valve regurgitation, which in both cases
can be either acquired or congenital, can lead to volume over-
load with severe chamber dilatation and decreased
mass/volume ratio. Atrial dilatation can be helpful in the as-
sessment of valve incompetence.
Other conditions of compensatory hypertrophy
(Fig. 8)
Heart hypertrophy is a common finding in dilated hearts due
to significant ischemic scarring (postmyocardial infarction
chronic ischemic heart disease) and inflammatory or infiltra-
tive cardiomyopathies. In these instances, hypertrophy com-
pensates for the loss of vital myocardium. In particular, in the
setting of ischemic heart disease, regional wall changes are a
common feature, when segments of myocardium adjacent to
the scarred area undergo a “compensatory” hypertrophy.
Papillary muscles and infero-basal LV wall hypertrophy
and fibrosis, due to localized hypercontractility triggered by
the prolapsing leaflet, have been reported in mitral valve pro-
lapse [55, 56].
Fig. 9 Left ventricular noncompaction cardiomyopathy/dilated. Note the
left ventricular cavity enlargement, thinning of the compact layer with
prominent trabeculae of the left ventricular free wall. Note the endocardial
fibroelastosis following the outline of the trabeculae






Fig. 11 Histology of cardiac myocyte hypertrophy. Note the increased
cardiac myocyte diameter and the bizarre, irregular, and hyperchromatic
nuclei (hematoxylin eosin stain bar = 50 micron). A close-up (bar = 100
micron) is seen in the insert
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Compensatory hypertrophy of the remaining myocardium
has also been described in arrhythmogenic cardiomyopathy.
Hypertrophy of the trabeculae is a well-known epiphenome-
non accompanying subepicardial, midmural, or transmural
fibro-fatty replacement of the ventricular myocardium
[57–59].
Cardiac hypertrophy with a complex/mixed
pathophysiology
Diabetes Diabetic heart disease is a distinct pathology inde-
pendent of co-morbidities such as coronary artery disease and
hypertension. Cardiac remodeling is influenced by hypergly-
cemia, dyslipidemia, and hyperinsulinemia which promote β-
adrenergic signaling leading to hypertrophy and eventual car-
diac failure. Additionally, volume-loading from obesity can
contribute to the cardiac hypertrophy [60].
Obesity Obesity-associated LVH can be explained by in-
creased blood cardiac output due to longstanding excess of
body weight, and probably highmetabolic activity of the large
load of fat tissue. It occurs especially in patients presenting
morbid obesity, which may lead to the so-called obesity car-
diomyopathy with congestive heart failure. Additionally, hy-
pertension and obstructive sleep apnea contribute to the car-
diac hypertrophy in the morbid obese. Normal weight, con-
centric and eccentric types of LVH, and biventricular
hypertrophy and excess of epicardial fat and fatty infiltration
of RV have been reported [61].
Congenital heart disease The spectrum of congenital
malformations of the heart and great vessels is highly di-
verse, with either shunts between pulmonary and systemic
circulation, abnormal insertions of vasculature or
obstructive/stenosing lesions as their main features. They
can occur as single lesions or in combinations, but invari-
ably lead to significant aberrant hemodynamic flow pat-
terns in the heart. Adaptive changes start early after birth,
and involve one, two, three, or four of the cardiac cham-
bers depending on the type of underlying malformation
(Fig. 10). At present, most patients with congenital heart
disease undergo surgical correction or palliation with sur-
vival until adult age. However, nearly all these patients
show at least to some extent a remaining morbidity, which
relates to the initial lesion or the surgical repair. Detailed
patterns of hypertrophic remodeling for each type of mal-
formation have been recently reviewed [62].
Drugs Cardiac structural abnormalities in drug abusers are
observed essentially in chronic cocaine addicts, and include
LVH with increased heart weight, small vessel disease, and
atherosclerotic coronary artery disease [63]. Different hypoth-
eses have been postulated to explain LVH in cocaine abusers,
such as the transient elevation of systolic blood pressure after
cocaine use or the direct stimulation of myocardial α-
Fig. 12 Histology of
hypertrophic cardiomyopathy. a
Myocyte bundle disarray
(hematoxylin eosin stain). b
Myocyte bundle disarray
(trichrome stain). c Interstitial
fibrosis (trichrome stain). d
Replacement-type fibrosis with
small vessel disease (trichrome
stain). All bar = 100 micron
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adrenergic receptors [64]. Amphetamine and its derivatives as
ecstasy cause an identical type of cardiotoxicity as cocaine
[65]. Androgenic anabolic steroids are known to cause cardiac
hypertrophy with increased mass, fibrosis, and substantial im-
pairment of LV systolic and diastolic function [66].
Gray zones
Athlete’s heart Intense and chronic athletic training is associated
with LV remodeling, including an increase in wall thickness,
cavity size, and mass. The extent of morphological cardiac
changes depends on a variety of factors such as body size, gen-
der, discipline of sport, ethnicity, and, likely, genetic factors. The
type of training (endurance vs. strength training) is of special
importance. Endurance exercise predominantly produces vol-
ume load on the LV and strength exercise causes largely a pres-
sure load. The adaptations to intensive endurance or strength
training can cause the so-called athlete’s heart [67]. These
changes are considered generally as physiological and reversible
in most cases. However, training-induced modifications may
mimic the remodeling of pathological hypertrophy and the dif-
ferential diagnosis between the athlete’s heart and some patho-
logical conditions as HCM may be challenging [68].
Cardiac hypertrophy in people of African descent LVH is
more common in this ethnic group, and is often associated
with a greater severity of arterial hypertension [69]. Arterial
hypertension is due to a combination of genetic, endocrine,
and hemodynamic factors [70].
Basal-septal hypertrophy in the elderly In a subset of elderly
normal subjects, with normal wall thickness elsewhere, basal
septum hypertrophy is an age-related anatomic variant [71].
Left ventricular noncompaction (or hypertrabeculation) (Fig. 9)
It is characterized by one or more LV segments, and sometimes
biventricular, with excess trabeculations and deep
intertrabecular recesses making up 2/3 of the wall with thinning
of the compact layer. Papillary muscles need to be excluded
when measuring the noncompacted layer. In children it can be
seen in association with congenital heart disease and pediatric
cardiomyopathies like Barth syndrome. In adults it shares phe-
notypic overlap with DCM and HCM and it is still debated
whether it should be considered as a separate entity [72, 73].
The genetic basis is heterogeneous, often coinciding with that
of cardiomyopathies and/or congenital heart disease [74].
Idiopathic LVH It is defined as LVH, usually concentric, at
gross examination with hypertrophic cardiac myocytes in the
absence of disarray at histology after extensive sampling.
There is no history of hypertension or other explanations for
the LVH [75, 76].
Right ventricular hypertrophy (Fig. 10)
The mechanisms that lead to the distinct forms of LVH will
obviously also apply to the RV. Moreover, both ventricles
cannot be seen as separate entities. Hypertrophy of either the
RV or LV alters the shape of the ventricular septum which
may have significant effects on the ventricular geometry.
Primarily RV pressure overloadmay be due to pulmonary
valve stenosis, primary pulmonary hypertension, chronic pul-
monary disease, or left-sided heart disease with left heart fail-
ure. Chronic pressure overload leads to myocardial hypertro-
phy, which is essentially of concentric type. However, on the
longer term also, volume adaption ensues, whichmeans that at
autopsy many cases show in fact an eccentric type of RV
hypertrophy with dilated ventricle. In such cases, the interven-
tricular septum has an almost straight configuration, which
affects the LV geometry.
Pseudo-hypertrophy of the RV when epicardial fat merges
into underlying myocardium can occur in the setting of obe-
sity and arrhythmogenic cardiomyopathy, in the latter associ-
ated with fibrosis.
Acute inflammation or ischemia
Increased ventricular and septal wall thickness due to massive
interstitial edema with preserved cardiac myocytes size
(“pseudo-hypertrophy”) can be found in the setting of acute
myocarditis or ischemic reperfusion injury such as after
prolonged cardiac arrest with resuscitative maneuvers.
Histology and clinical history can be of help for differential
diagnosis [77, 78].
Referral for second opinion in cardiovascular
pathology
If the autopsy is carried out in a general or forensic pathology
service without expertise in cardiovascular pathology, the en-
tire heart should be retained and sent to a specialized center
with that expertise (reference network) to support routine
workup [2, 79]. The referring pathologist/forensic performing
the autopsy should examine the heart in a conservative way so
that all the main structures are still appreciable in case of
referral. If the heart cannot be retained then cardiac samples
taken as indicated above should be processed to slides and
sent for an expert opinion. It is essential that extensive photo-
graphic documentation with a ruled reference scale is made,
indicating where individual blocks are taken. At least one
transverse section of the heart including the LV and RV




Indication for postmortem genetic testing should be integrated
into the multidisciplinary management of sudden cardiac
death [80]. The finding of a hypertrophied heart at postmor-
tem opens the doors to a potentially inherited cardiovascular
disease and first-degree familymembers should be referred for
clinical/genetic counseling [2]. The collection and storage of
frozen of blood or tissue samples should be always guaranteed
in the course of an autopsy, together with detailed cardiac
pathology phenotype, for possible genetic testing in case of
a suspected inherited disease.
Abbreviations BSA, body surface area; CMR, cardiac magnetic reso-
nance; CT, computed tomography; CTR, cardiothoracic ratio; DCM, di-
lated cardiomyopathy;HCM, hypertrophic cardiomyopathy; LV, left ven-
tricle; LVH, left ventricular hypertrophy; LVNC, left ventricular
noncompaction; LVOT, left ventricular outflow tract; PMCT, postmortem
computed tomography; PMMR, postmortem magnetic resonance; RV,
right ventricle; TEM, transmission electron microscopy
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